The Michael J. Fox Foundation for Parkinson's Research awarded Rhythm Pharmaceuticals a $1.4 million grant to support a midstage study of ghrelin agonist RM-131, its drug candidate for refractory constipation, which affects many Parkinson's disease patients. "As we continue our work to advance RM-131 in the clinic, we are excited to join with The Michael J. Fox Foundation to address this important unmet need in Parkinson’s disease," Rhythm CEO Keith Gottesdiener said.
Published in Brief: